TSCAN THERAPEUTICS, INC. Stock Issued During Period, Value, New Issues
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- TSCAN THERAPEUTICS, INC. stock issued during period, value, new issues for the quarter ending 2024-12-31 was $0.00.
- TSCAN THERAPEUTICS, INC. stock issued during period, value, new issues for the quarter ending 2024-09-30 was $0.00.
- TSCAN THERAPEUTICS, INC. stock issued during period, value, new issues for the quarter ending 2024-06-30 was $33.13M, a 21.89% decline year-over-year.
- TSCAN THERAPEUTICS, INC. stock issued during period, value, new issues for the quarter ending 2023-12-31 was $0.00.
- TSCAN THERAPEUTICS, INC. stock issued during period, value, new issues for fiscal 2024 was $33.13M, a 21.89% decline from fiscal 2023.
- TSCAN THERAPEUTICS, INC. stock issued during period, value, new issues for fiscal 2023 was $42.41M, a 21876.17% increase from fiscal 2022.
- TSCAN THERAPEUTICS, INC. stock issued during period, value, new issues for fiscal 2022 was $193.00K, a 99.78% decline from fiscal 2021.
- TSCAN THERAPEUTICS, INC. stock issued during period, value, new issues for fiscal 2021 was $89.65M.
| Period end | Stock Issued During Period, Value, New Issues 3 month | Stock Issued During Period, Value, New Issues 12 month |
|---|---|---|
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-04 | $33.13M 10-K · filed 2026-03-04 |
| 2024-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | |
| 2024-06-30 | $33.13M 10-Q · filed 2025-08-12 | |
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-05 | $42.41M 10-K · filed 2025-03-05 |
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | |
| 2023-06-30 | $42.41M 10-Q · filed 2024-08-12 | |
| 2022-12-31 | $193.00K 10-K · filed 2024-03-06 | |
| 2021-12-31 | -$1.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-08 | $89.65M 10-K · filed 2023-03-08 |
| 2021-09-30 | $89.65M 10-Q · filed 2022-11-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CERO THERAPEUTICS HOLDINGS, INC. (CERO) | United States | $0.007B | |
| CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. (CELZ) | United States | $0.006B | |
| AIM ImmunoTech Inc. (AIM) | United States | $0.006B | |
| Senti Biosciences Holdings, Inc. (SNTI) | United States | $0.011B | -0.70 |
| IN8BIO, INC. (INAB) | United States | $0.012B | -0.76 |
| PharmaCyte Biotech, Inc. (PMCB) | United States | $0.005B | |
| BRAINSTORM CELL THERAPEUTICS INC. (BCLI) | United States | $0.013B | -1.05 |
| INTENSITY THERAPEUTICS, INC. (INTS) | United States | $0.013B | -1.08 |
| WINDTREE THERAPEUTICS INC /DE/ (WINT) | United States | $0.003B | -0.32 |
| VivoSim Labs, INC. (VIVS) | United States | $0.003B |